Citius Oncology, Inc. (CTOR) analyst actions
Rating and price-target actions on CTOR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CTOR overview →
2 measured CTOR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies | Press release | +0.00% | -0.84% | |
| Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers | Press release | -2.00% | +0.50% |
Keep exploring
More CTOR: earnings → · SEC filings → · CTOR overview →